|

Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP

RECRUITINGSponsored by French Africa Pediatric Oncology Group
Actively Recruiting
SponsorFrench Africa Pediatric Oncology Group
Started2021-11-15
Est. completion2028-12-31
View on ClinicalTrials.gov →

NCT04794296

Summary

The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.

Eligibility

Inclusion Criteria:

Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2

\-

Exclusion Criteria:

ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21

Conditions2

CancerChildhood ALL

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.